The recently described CC chemokine, 6C-kine, is unique in that it contains -six rather than the usual four conserved cysteines typical of this family. Furthermore, murine 6C-kine binds to one of the CXC chemokine receptors CXCR3, in addition to its other known receptor CCR7. We have shown that two other ligands of CXCR3, IP-10 and MIG, are potent inhibitors of tumor growth in severe combined immunode®-ciency (SCID) mice. We postulated that murine 6C-kine may also inhibit tumor growth via inhibition of angiogenesis in this model. SCID mice (n 6 per group) inoculated with A549 human lung cancer cells were treated with either 6C-kine (100 ng intra-tumor injection every other day) or control protein for 8 weeks. Tumors from murine 6C-kine-treated mice (288 26 mm 3 ) were signi®cantly smaller than tumors from control treated mice (788 156 mm 3 , P 0.005). Additionally, murine 6C-kine reduced metastases compared with controls (0.5 0.3 vs 3.0 1.2 metastases per animal, P 0.05). Tumor vascularity (as assessed by vessel density counting) was reduced in murine 6C-kine-treated mice compared with controls. Murine 6C-kine had no direct eect on proliferation of A549 cells, and there were no dierences in the in®ltration of leukocyte sub-populations, assessed by¯ow cytometry, in the treatment groups. Interestingly, human 6C-kine, unlike murine 6C-kine, does not bind CXCR3 and had no anti-tumor eect in the same model. These data suggest that murine 6C-kine has anti-tumor eects independent of its leukocyterecruiting activity. Furthermore, while not con®rmatory, these data lend further support to the fact that CXCR3 may be the receptor for angiostatic CXC chemokines.
Introduction
The dependence of tumor growth upon angiogenesis has been the subject of intense research in recent years. It is the balance between angiogenic and angiostatic factors that regulates angiogenesis in any tissue, and studies of tumor associated angiogenesis have yielded many new factors capable of regulating this process. A family of molecules known as chemokines is important in the regulation of angiogenesis [1] . The CXC chemokine family is named after the amino acid sequence describing the ®rst of two highly conserved cysteine amino acid residues, separated by a third non-conserved amino acid. This family can be further divided into those which are angiogenic and those which are angiostatic, based upon the presence (angiogenic) or absence (angiostatic) of a three-amino-acid motif immediately preceding the ®rst conserved cysteine in the primary structure, the glutamic acid±leucine±arginine (ELR) motif. The ELR motif was ®rst found to be important in binding and activation of neutrophils [2] . However, we have shown that the ELR motif is also critical in determining the angiogenic activity of these molecules [3] .
We and others have shown that the CXC chemokines may regulate tumor-derived angiogenic activity in a variety of cancers, including lung [1] , gastric [4] , prostate [5] , and CNS [6] tumors, as well as in models of Burkitt's lymphoma [7] and melanoma [8, 9] . In this study we report that a member of the CC chemokine family, known as 6C-kine, has anti-tumor activity that is attributable to its angiostatic property. C-kine has six cysteines rather than the four cysteines that characterize most of the CC chemokine family [10] .
6C-kine (also known as secondary lymphoid chemokine-SLC, exodus 2, or CCL21) is important in recruiting activated dendritic cells and T-cells to lymphoid follicles. Although it is classi®ed as a CC chemokine, murine 6C-kine has been shown to bind to the CXC chemokine receptor, CXCR3 [11] . Interestingly, while murine 6C-kine binds CXCR3, human 6C-kine binds neither human nor murine CXCR3 [12] . Human 6C-kine does bind the other known 6C-kine receptor, CCR7, in both murine and human form [12] . Binding to CXCR3 is a property that murine 6C-kine shares with two of the angiostatic CXC chemokines, interferon-inducible protein 10 (IP-10), and monokine induced by interferon-c (MIG). We hypothesized that, similar to other CXCR3 ligands, murine 6C-kine would have anti-tumor activity in a SCID mouse model of human non-small-cell lung cancer (NSCLC) that is dependent upon angiostatic activity. To test this hypothesis, we used a well-characterized chimeric model of human NSCLC in SCID mice and treated animals with intratumor injections of 6C-kine or vehicle control. SCID mice were employed to isolate the angiostatic eect of 6C-kine from the known immune-mediated anti-tumor eects of 6C-kine as demonstrated by Sharma and colleagues [13] . We found that 6C-kine inhibits tumor growth and metastasis in SCID mice, and that this inhibition is associated with a reduction in tumor vascularity with no change in leukocyte in®ltration. This suggests that other ligands of CXCR3, either endogenous or synthetic, might be important therapeutic options for angiostatic therapy of human cancer.
Materials and methods

Reagents
Murine and human 6C-kine were a generous gift from R&D Systems. Antibodies for¯ow cytometry of tumor digests were as follows: Anti-CD45 (tri-color), FITC-anti-mouse macrophage, phycoerythrin (PE)-anti-mouse NK cells (DX5 clone), and PE-antimouse neutrophil (GR-1) were purchased from CalTag Laboratories (Burlingame, Calif.). Dako (Carpinteria, Calif.) horseradish peroxidase-conjugated antibodies to factor VIII-related antigen were used for immunohistochemical staining of tumor vasculature. Antibodies to rabbit anti-factor VIII-related antigen and pre-immune rabbit-IgG were purchased from Biomeda (Foster City, Calif.). The FITC-conjugated goat anti-rabbit IgG (Pharmingen, San Diego, Calif., USA) was used as a secondary antibody.
Human NSCLC cell lines
The A549 (adenocarcinoma) cell line (American Type Culture Collection, Rockville, Md.) was maintained in sterile 150 cm 2 tissue culture¯asks. Cells were cultured and passaged at 37°C in 95% room air/5% CO 2 . For proliferation assays, 5´10 3 cells were plated in each well of a 96-well plate and allowed to grow for 24 h, serum starved for 24 h, then treated with varying concentrations of 6C-kine in medium with 1% serum. After 24 h, cell number was assessed using a non-radioactive cell proliferation assay according to the manufacturer's instructions (CellTiter 96 AQ, Promega, Madison, Wis.). For inoculation into mice, the cells were trypsinized, harvested, washed, and resuspended in serum-free medium at a concentration of 1´10 7 cells/ml.
Human NSCLC-SCID mouse chimeras Four-to six-week-old female CB17-SCID mice (Taconic Farms, Germantown, N.Y.) with serum Ig <1 lg/ml were injected subcutaneously with human NSCLC cells (1´10 6 cells in 100 ll) into each¯ank, and weekly tumor measurements were performed as previously described [14] . Mice received intra-tumor injections of either mouse or human recombinant 6C-kine (100 ng in 20 ll of sterile saline every other day) or vehicle [phosphate-buered saline (PBS) with 0.1% human serum albumin (HSA)] beginning at the time of tumor inoculation. The lungs were in¯ated with 4% paraformaldehyde and ®xed in paran. An investigator blinded to treatment condition counted visible metastases under an illuminated magni®er (4´). Lungs were then embedded in paran, sectioned, and H&E-stained specimens (two from each mouse) were subjected to digital image analysis using NIH Image 1.55 software as previously described [15] . All animals were handled in accordance with the 1985 revised principals of laboratory animal care (NIH publication No. 85±23), as well as protocols established by the University of Michigan Unit for Laboratory Animal Medicine.
Tumor specimens from SCID mice were processed as follows: One portion was ®xed in 4% paraformaldehyde for histologic analysis and immunohistochemistry. Another portion of tumor taken with a standard 6 mm punch biopsy tool (to equalize the volume of tumor between samples), was minced into single cell suspension using the Dako Medimachine with 50 lm blade and ®lter combination. Cells were then centrifuged at 300g for 10 min. Red blood cells were lysed, and cells were washed in PBS and resuspended in¯uorescent antibody (FA) buer [1% FA buer (Difco, Detroit, Mich.), 1% FCS and 0.1% azide, 1´10 6 cells/ml] and maintained at 4°C for the remainder of the staining procedure.
Quanti®cation of in®ltrating leukocytes
One hundred microliters of cells from each tumor was then added to each of eight wells. Cells were blocked with Fc-block (Pharmingen) for 10 min at 4°C, then labeled with anti-mouse leukocyte antibody (CD45-tricolor) or isotype control for 30 min at 4°C. Cells were washed in FA buer, then a second antibody was added for 30 min at 4°C, one each of the following for each tumor specimen: FITC-conjugated Mac-1 (for macrophages) or isotype control, PE-conjugated DX5 antibody (for NK cells) or isotype control, FITC-conjugated anti-GR-1 (for neutrophils) or isotype control. One unstained specimen for each tumor was used for setting gates for the forward and side scatter characteristics. FACS analysis was then employed to determine the degree and type of leukocyte in®ltration.
Macrophages were localized and quantitated in paranembedded A549 tumor specimens with 1:1,000 rabbit anti-murine macrophage antibody (CalTag) from mice treated with either 6C-kine or control using our previously described method [16, 17] . Fast Red (BioGenex, San Ramon, Calif.) reagent was used for chromogenic localization of murine macrophages, and sections were counter-stained with Mayer's hematoxylin. Tumor sections were then examined under 400´magni®cation and cells counted. A total of four ®elds per tumor section and six tumors per treatment group were counted. Results were expressed as the number of macrophages per high-power ®eld (hpf; 200´).
Quantitation of vessel density
For FACS quanti®cation of tumor vascularity, an additional 100 ll tumor cells (from the tumor minced at the time of sacri®ce) was labeled with rabbit anti-factor VIII-related antigen antibodies to recognize tumor-associated endothelial cells. Pre-immune rabbit IgG was used as a control. FITC-conjugated goat anti-rabbit IgG was used as a secondary antibody to detect cells expressing factor VIII-related antigen. Tumor vasculature was expressed as the percentage of cells from the tumor that were positive for factor VIII-related antigen. Quantitation of histologic vessel density was performed on paran-embedded specimens of tumors from mice treated with either 6C-kine or control, and stained with antibody to factor VIII-related antigen conjugated to horseradish peroxidase (Dako) using our previously described method [14] . Specimen identity was undisclosed and sections scanned at low magni®cation (40´) to identify vascular``hot spots''. Areas of greatest vessel density were then examined under higher magni®cation (200´) and counted. Any distinct area of positive staining for factor VIIIrelated antigen was counted as a single vessel. Two tumor sections per animal were stained, and a single``hot-spot'' per section was counted. Results were expressed as the number of vessels per hpf (200´).
Statistical analysis
The animal studies involved a minimum of 12 human NSCLC tumors or six SCID mice for each treatment group. Data were evaluated by Student's t-test or by the Mann-Whitney test for non-normally distributed data (e.g., size of metastases), and were considered signi®cant if P values were less than 0.05. Results are presented as means SEM. Data were analyzed on a Macintosh 8600 computer using the Statview 4.5 statistical software package (Abacus Concepts, Berkeley, Calif., USA).
Results
Murine 6C-kine inhibits tumor growth
The SCID mice were injected with 1´10 6 A549 cells in the subcutis on each¯ank. One group (n 6) of mice received 100 ng murine 6C-kine (murine 6C-kine) injected into the tumor three times weekly. A second group received vehicle as control (0.1% HSA in PBS). The dose and timing chosen were based on our previously published experience using IP-10 in this animal model [15] . Tumors from m6C-kine-treated mice (288 26 mm 3 ) were 63% smaller than tumors from control-treated mice (784 156 mm 3 , P 0.005; Fig. 1 ). Additionally, metastases were signi®cantly reduced in m6C-kine-treated mice (0.5 0.3 metastases per animal) compared with control-treated mice (3.0 1.2 metastases per animal, P 0.05; Fig. 2 ).
Leukocyte in®ltration is not altered by treatment with m6C-kine As a chemokine, 6C-kine may attract leukocytes to the tumor, which could contribute to anti-tumor activity. While these SCID mice do not have T-or B-cell function, m6C-kine might also reduce tumor growth by attracting tumoricidal macrophages or NK cells to the tumor. In order to investigate this possibility, we performed FACS analysis to quantify the degree of tumor in®ltration by sub-populations of leukocytes in m6C-kine-compared with control-treated mice. Tumor digests from m6C-kine-treated mice, as compared to control-treated mice, revealed no signi®cant dierences in the degree of in®ltration of macrophages (Mac-1), NK cells (DX5), or neutrophils (GR-1; Table 1 ). As a further con®rmation of this ®nding, we quanti®ed macrophage in®ltration in histologic sections of A549 tumors from m6C-kine-and control-treated mice. The number of macrophages per hpf (400´) was similar in m6C-kine-treated (3.2 0.7) and control-treated groups (3.8 0.5; P 0.5).
Vascularity of A549 tumors is reduced in m6C-kine-treated mice
As demonstrated by Soto and colleagues [11] , m6C-kine has angiostatic activity. In order to determine whether the reduction in tumor growth in m6C-kine-treated mice was due to inhibition of angiogenesis, we performed FACS analysis on tumor digests to quantify the percentage of cells expressing factor VIII-related antigen. Tumors from mice receiving m6C-kine had a reduced percentage of endothelial cells as determined by FACS analysis (4.4 0.6 vs 6.5 0.4%, P 0.005; Table 2 ). We further con®rmed this by performing immunohistochemical staining of vessels using antibodies to factor VIII-related antigen on paran embedded tumor sections from m6C-kine-and control-treated mice. Vessel density was determined in vascular``hot-spots'' scanned at low magni®cation (40´), counting under a high power ®eld (200´). Vessel density was signi®cantly lower in m6C-kine-treated mice (6.8 0.9 vessels/hpf) than in control mice (11.4 0.9 vessels/hpf, P 0.001; Table 2 ).
m6C-kine does not aect proliferation of NSCLC cells
In order to exclude the possibility that the reduction in tumor growth seen in mice treated with 6C-kine was due to a direct anti-proliferative eect of m6C-kine upon A549 cells, we performed proliferation assays in vitro in the presence of varying doses of m6C-kine. Proliferation was assessed using a non-radioactive proliferation assay. A549 cell proliferation was not reduced in the presence of any concentration of m6C-kine from 1 to 100 ng/ml (approximately 70 pM to 7 nM; Fig. 3 ).
Human 6C-kine (h6C-kine) does not inhibit tumor growth
While m6C-kine has been found to bind CXCR3, human 6C-kine does not share that property [11, 12] . We tested h6C-kine in the same animal model to determine whether this lack of CXCR3 binding would be associated with a lack of angiostatic activity (and therefore a lack of anti-tumor activity in SCID mice). In contrast to m6C-kine, treatment of A549 tumor-bearing SCID mice with h6C-kine had no eect on tumor growth compared Fig. 4 ). Metastases were not reduced in h6C-kine-treated mice compared with controls (2.7 1.0 vs 3.2 1.0 metastases per animal, P 0.7).
Discussion
This study demonstrates anti-tumor activity of m6C-kine in a T-and B-cell-independent model. Recently, Sharma and co-workers used a syngeneic mouse model of lung cancer to demonstrate that 6C-kine has potent T-celldependent anti-tumor activity [13] . These authors also demonstrated the development of protective immunity after re-challenge with tumor cells, as well as adoptive transfer of tumor immunity to naõÈ ve animals with T-cells from mice``cured'' of their tumors. In contrast to our current ®ndings, Sharma and colleagues found that 6C-kine did not inhibit tumor growth of the LLC cell line in SCID mice. A possible explanation for the discrepancy would be the dierence in the growth rates of the two dierent cell lines used. It is possible that the angiostatic activity of 6C-kine is more eective in slower growing tumors. The LLC cell line used by Sharma et al. grows more rapidly than the A549 cell line. Interestingly, despite the lack of evidence for angiostatic activity in the Sharma study, the authors found that tumors from mice treated with 6C-kine also had a greater frequency of cells expressing interferon-c [13] . Interferon-c by itself can promote an angiostatic environment by inducing the angiostatic factors IP-10 and MIG, and suppress the expression of angiogenic CXC chemokines [18] . Indeed, the measurement of tumor-associated cytokine levels in their study demonstrated an increase in the levels of IP-10 and MIG, as well as a decrease in the levels of VEGF from tumors of mice treated with m6C-kine. Our data using a SCID mouse model suggest that m6C-kine also provides anti-tumor activity that is due to inhibition of angiogenesis. While 6C-kine has been demonstrated to have direct angiostatic activity [11] , the ®ndings of Sharma and colleagues, combined with those in the present study, suggest that some indirect angiostatic activity may be relevant to 6C-kine's anti-tumor activity as well.
The signi®cance of our ®ndings is twofold. First, the ability of a single molecule to inhibit angiogenesis [11] and attract lymphocytes [10, 19] makes it an attractive candidate as a therapeutic agent. Second, the implications of our ®ndings support the notion that CXCR3 may be another important therapeutic target for antiangiogenic therapy.
CXCR3 is a receptor for two CXC chemokine ligands IP-10, and MIG. We have previously shown that members of the CXC chemokine family are important regulators of angiogenesis. We have found IP-10 and MIG, two angiostatic CXC chemokines, are potent endogenous angiostatic factors in non-small cell lung cancer (NSCLC) [15, 20] . IP-10 and MIG also share the property of being interferon-inducible chemokines, and other investigators have demonstrated that these two chemokines may be responsible for the anti-tumor activity of interleukin-12 [21±23]. While CXCR3 is a receptor for both of these chemokines, no studies to date have demonstrated that it is the receptor that mediates the angiostatic activity of IP-10 and MIG. Soto and colleagues cloned murine CXCR3, and in screening a panel of chemokines for additional ligands found that m6C-kine was able to induce calcium¯ux in CXCR3-transfected CHO cells [11] . They also found that m6C-kine inhibited angiogenesis in the rat corneal micropocket assay [11] . The ®nding that m6C-kine inhibits angiogenesis, while not de®nitive evidence, supports the notion that CXCR3 mediates the angiostatic eects of these molecules. In further support of this is our ®nding that human 6C-kine, which does not bind to murine CXCR3 [12] , but does bind to the other known murine receptor for m6C-kine, CCR7 (unpublished observations), does not inhibit angiogenesis or tumor growth in our model. It is important to note that the lack of anti-tumor activity of human 6C-kine in SCID mice does not preclude its use as an anti-tumor agent in humans, given its ability to attract activated dendritic cells and T-cells through CCR7.
It is also interesting to note that, similar to IP-10 [15] , administration of m6C-kine directly into the tumor inhibits distant metastases. It is unlikely that the quantity of m6C-kine administered (100 ng every other day), reaches sucient systemic levels to have a direct eect on distant metastases. Rather, we propose that this is an indirect eect on metastases by inhibiting tumor angiogenesis. One hallmark of angiogenesis is increased permeability of the vessel wall [24] , a factor likely to facilitate metastases [25] . Inhibition of angiogenesis will probably also result in reduced access to the vasculature by tumor cells.
In summary, we have con®rmed the anti-tumor ecacy of m6C-kine, a CC chemokine with angiostatic properties. The presence of this anti-tumor activity in a SCID mouse model demonstrates that it is T-and B-cell independent. While the mechanism for the angiostatic activity of m6C-kine awaits further studies, it is attractive to postulate that CXCR3 is the mediator of this activity since this receptor also binds other angiostatic chemokines. Our ®ndings suggest that other agonists of CXCR3 should be sought for their potential angiostatic activity.
